Prognostic value of osteopontin in patients with hepatocellular carcinoma
A systematic review and meta-analysis

Tingting Sun, MD, Peng Li, MD, Diwen Sun, MD, Qingao Bu, MD, Guoqiang Li, MD

Abstract
Purpose: The prognostic value of tissue and serum osteopontin (OPN) in hepatocellular carcinoma (HCC) remain controversial. The aim of present meta-analysis was to evaluate the prognostic value of OPN in patients with HCC.

Methods: Eligible studies were systematically searched by PubMed, EMBASE, and Google scholar. A meta-analysis of 12 studies included 2117 cases was performed to estimate the association between OPN level and overall survival (OS), disease-free survival (DFS) in HCC patients. Subgroup analyses were also performed in the meta-analysis.

Results: The pooled data of studies showed that high OPN level was significantly associated with poor OS (hazard ratios [HR] 1.84; 95% confidence intervals [CI] 1.54–2.20; P = .000) and DFS (HR 1.67; 95% CI 1.40–1.98; P = .000) in HCC. Furthermore, in subgroup analysis, high tissue based OPN by immunohistochemistry detection and serum-based OPN by enzyme-linked immunosorbent assay (ELISA) detection were both significantly associated with OS (tissue: HR 1.88; 95% CI 1.53–2.31; P < .0001; serum: HR 2.38; 95% CI 1.58–3.59; P < .0001). Simultaneously, we also found that OPN expression was positively associated with stage (odds ratios [OR] 5.68; 95% CI 3.44–7.75), tumor size (Size ≤ 5 cm vs > 5 cm; OR 2.001; 95% CI 1.036–3.867).

Conclusion: The current evidence indicates that OPN could serve as a prognostic biomarker and a potential therapeutic target for HCC.

Abbreviations: CI = confidence intervals, DFS = disease-free survival, ELISA = enzyme-linked immunosorbent assay, HCC = hepatocellular carcinoma, HR = hazard ratios, IHC = immunohistochemistry, NOS = Newcastle-Ottawa Scale, NR = not reported, OPN = osteopontin, OR = odds ratios, OS = overall survival.

Keywords: hepatocellular carcinoma, meta-analysis, osteopontin, prognosis

1. Introduction
Hepatocellular carcinoma (HCC) is 1 of the most aggressive malignant neoplasms worldwide and the third causes of cancer-related mortality.[11] Though advances in diagnostic techniques and treatments could improve the prognosis of HCC patients, the patients prognosis remains very poor owing to high rate of recurrence.[2,3] So it is urgent to identify novel biological markers that could predict the prognosis and metastatic recurrence of patients with HCC.

Osteopontin (OPN) is a multifunctional phosphoprotein, which could be expressed in different cell types, Including T lymphocytes, macrophages and osteoclasts.[4–6] Recent studies have demonstrated that OPN plays a crucial role in tumorigenesis and metastasis.[7,8] Earlier studies have shown that increased OPN levels are linked to poor prognosis of HCC,[9,10] and promote HCC metastasis.[11–13] Moreover, OPN overexpression has been detected in different solid tumors, including lung cancer,[14] breast cancer,[15,16] gastric cancer,[17] HCC,[18] colorectal cancer[19] and so on. It is suggested that OPN overexpression can predict the prognosis of carcinomas. However, the relationship between OPN expression and prognostic outcomes in HCC patients were controversial and inconclusive. Therefore, we conducted this meta-analysis to systematically and comprehensively evaluate the prognostic value of OPN in HCC.

In this study, we systematically reviewed studies to explore the prognostic significance of OPN for overall survival (OS) and disease-free survival (DFS) in HCC patients. And the correlation between OPN expression and clinicopathological features was also discussed.

2. Material and methods
2.1. Identification and selection of studies
Studies were identified by searching PubMed, EMBASE and Google Scholar databases covering all papers published update to October 31, 2017. The search strategy was used the following terms: [OPN or SPP1 [MESH] or OPN or sialoprotein 1 [TEXT WORD]] AND (carcinoma, hepatocellular [MESH] or HCC [TEXT WORD]). Studies in English were eligible for inclusion.
Additionally, the appropriate references of the identified studies were also checked to identify additional suitable articles. Once studies were found with overlapping data published by the same research center, only the paper with most complete data was included. This project was approved by the Institutional Review Board of Shengli Oilfield Central Hospital.

### 2.2. Inclusion and exclusion criteria

Eligible studies in this meta-analysis should meet the following criteria:

1. evaluated the relationship between OPN expression and survival outcomes of HCC;
2. reported explicit methods for the measurement of OPN expression in the primary HCC;
3. Examined the association of OPN expression in HCC patients with survival, recurrences, and a series of clinicopathological parameters;
4. Provided the hazard ratios (HR) or odds ratios (OR) with the 95% confidence intervals (CI) or sufficient data to calculate them;
5. have a maximum follow-up time exceeding 3 years;
6. editorial letters, comments or conference abstracts, reviews, and case reports were excluded.

### 2.3. Qualitative assessment

The Newcastle–Ottawa Scale (NOS) was used to assess the quality of included studies. The score was based on subject selection, comparability of subject, clinical outcome in the NOS. NOS score of 0 to 9 was used to indicate the quality of studies, and a score ≥ 6 denoted a high quality.

### 2.4. Data extraction

The studies information of this meta-analysis were retrieved by the reporting checklists of Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines. Data extracted from the studies included the following items:

1. publication information: first author’s last name, year of publication;
2. patients’ characteristic information: study population and regions, patients’ number, follow-up time;
3. OPN information: method, cut-off level, and relationship between OPN and OS, DFS or clinicopathological features; and
4. HR, 95% CI for survival analysis. If the relevant data were not reported (NR), items were treated as “NR (not reported)”. If without the HR and 95% CI in articles, Kaplan–Meier curve was available, data were extracted from graphical survival plot and HR was estimated.

### 2.5. Statistical analysis

Included studies were divided into 3 groups for analysis: those with data regarding OS, DFS, and clinicopathological parameters. OR and 95% CI were used to measure the association of OPN expression with clinical parameters, while the HR and 95% CI were used for the meta-analysis of survival rates. An OR > 1 indicated higher probability for later stage, larger tumor size or the presence of vascular invasion in the group with elevated OPN expression. While a combined HR > 1 implies a poor outcome for OPN overexpression in HCC patients. Heterogeneity of pooled results was conducted using I-squared statistic. If the $P < .10$ or $I^2 > 50\%$, we considered heterogeneity as significant heterogeneity, and then a random effect model was used. Otherwise, a fixed-effects model was used. subgroup analysis was evaluated the differences between HRs in included studies with different detection methods, treatments. Sensitivity analysis was performed to assess the reliability and validity of the meta-analysis. Both Begg funnel plot and Egger test were used to examine the publication bias. And we conducted a trim and fill analysis, which yields an effect adjusted for funnel plot asymmetry. Meta-analysis was conducted with STATA version 12.0 (STATA Corporation, College Station, TX). All $P$ values were 2 sides and $P < .05$ was considered statistically significant.

### 3. Results

#### 3.1. Studies selection and characteristics of studies

A total of 462 articles were initially identified via the search criteria delineated above. After screening of the title and abstract,29 articles were selected for detailed evaluation. Subsequently, 7 studies were excluded after full assessment due to lacking relevant survival data. Another 22 studies were selected. Of the 22 studies, 11 articles were reported by the same research group, and the patients were partly overlapping in these studies. To avoid duplicate counting, only 3 studies with complete data were included. Another 3 studies were also from the same study center, however, only the most complete 1 was selected. Finally, 12 studies were included in our meta-analysis (Fig. 1).

The basic characteristics of the 12 studies are summarized in Table 1. A total of 2117 patients from China, Taiwan, Korea, Austria, Thailand and Japan were enrolled with sample number ranging from 46 to 454. Regarding OPN detection in HCC, immunohistochemistry (IHC) was used in 8 studies, another 3 studies selected. immunohistochemistry (IHC) was used in 8 studies, another 3 studies used enzyme-linked immunosorbent assay (ELISA) to measure serum-based OPN expression. For HCC treatment, surgical resection as initial treatment was reported in 10 studies, and liver transplantation (LT) and transcatheter arterial chem otherapy (TACE) reported in 1 study respectively. OS was presented in all studies, however, DFS was only reported in 5 studies. Meanwhile, all studies had the follow-up times exceeding 3 years, with 7 studies more than 5 years. The NOS scores ranged from 5 to 8 with a mean of 6.1.

#### 3.2. OPN expression and clinicopathological parameters

To investigate the association between OPN expression and clinicopathological features, we conducted the meta-analysis. Five studies reported the association of tumor size ≥ 5 cm with OPN expression in HCC. Pooled data from all 4 studies showed high OPN expression was significantly associated with tumor size ≥ 5 cm (OR 2.001; 95% CI 1.036–3.867; $P = .039$). Two studies reported the association of the TNM stage with OPN expression. The combined data showed that increased OPN expression was significantly correlated to TNM stage (OR 5.680; 95% CI 3.443–7.758; $P = .000$). On the contrary, OPN overexpression was not found to be associated with age (OR 1.120; 95% CI 0.867–1.446; $P = .386$), Gender (OR 0.928, 95% CI 0.700–1.230; $P = .604$), HBsAg (OR 1.106; 95% CI 0.434–2.820; $P = .833$), Child–Pugh grade (OR 2.793; 95% CI 0.869–8.978; $P = .085$), AFP (OR 1.766; 95% CI 0.987–3.160; $P = .053$), Liver Cirrhosis
(OR 0.941; 95% CI 0.9410.653–1.355; P =.742), Vascular invasion (OR 2.56; 95% CI 0.92–7.12; P = .073), or tumor grade (OR 1.196; 95% CI 0.611–2.336; P = .601). These results suggested that HCC with overexpressed OPN exhibited aggressive biological behaviors (Table 2).

3.3. OPN expression and OS in HCC

Overall, all 12 studies, including 2117 patients, had a relationship between OPN expression and OS in HCC; and 10 presented reported data on OS and OPN expression in HCC initially treated by surgical resection. Heterogeneity among studies was statistically significant (P =.061, I² =43.3%), so a random-effects model was used. Pooled data suggested that high OPN expression was significantly correlated with reduced OS (HR 1.84; 95% CI 1.52–2.22; P = .000) (Table 3, Fig. 2A). Sensitivity analysis was performed and the overall trend was not changed by removing the studies 1 by 1 in Figure 2B. We also performed subgroup analysis for method and treatment. Subgroup analysis suggested that the detection method, either ELISA or IHC, of OPN expression had significantly influence for OS (ELISA: HR 2.38; 95% CI 1.58–3.59; P = .000; IHC: HR 1.88; 95% CI 1.53–2.31; P = .000), without significant heterogeneity in the data.

![Flow chart of the selection of the studies in the meta-analysis.](image)

**Table 1**

| References | Year | Patient source | No. of patient | Stage | Treatment | median age (year) | method | Cut off level | No. of "high" OPN | Follow-up (months) | Outcome | Scores |
|------------|------|----------------|----------------|-------|-----------|------------------|--------|---------------|------------------|-----------------|---------|--------|
| Pan et al  | 2003 | Taiwan         | 240            | I–IV  | S         | 55.86           | RT-PCR | ratio > 0.6   | 133              | 120             | OS      | 7      |
| Zhang et al | 2006 | China          | 101            | I–IV  | S         | 50.5            | ELISA  | >200 ng/ml    | 37               | 24              | OS/DFS  | 6      |
| Xie et al  | 2007 | China          | 72             | NR    | S         | 50.57           | IHC    | >20%          | 39               | 60              | OS/DFS  | 6      |
| Korita et al | 2008 | Japan          | 125            | NR    | S         | 63              | IHC    | focal or diffuse staining | 51 | 25–195 | OS | 5 |
| Yang et al | 2008 | China          | 302            | I-II  | S         | 52              | IHC    | >5%           | 73               | 4–121           | OS/DFS  | 7      |
| Kim et al  | 2009 | Korea          | 46             | I–IV  | TACE      | 59              | ELISA  | >1.85 log10 ng/ml | 13 | 2–42 | OS | 5 |
| Sieghert et al | 2011 | Austria | 125 | I–IV | LT | 54.54 | IHC | >10% | 40 | 3–195 | OS/DFS | 5 |
| Tsai et al | 2012 | Taiwan         | 100            | I–IV  | S         | 61              | IHC    | ≥25%          | NR               | 60              | OS      | 7      |
| Deng et al | 2013 | China          | 454            | NR    | S         | 55              | IHC    | ≥5%           | 227              | NR              | OS/DFS  | 6      |
| Jin et al  | 2014 | China          | 305            | I–IV  | S         | 55              | IHC    | ≥10%          | 212              | 36              | OS      | 7      |
| Ying et al | 2014 | China          | 90             | NR    | S         | 54.51           | IHC    | score > 2     | 59               | 36              | OS      | 7      |
| Chimparlee et al | 2015 | Thailand | 157 | NR | S | 61 | IHC | >133 ng/ml | 79 | NR | OS | 5 | |

DFS = disease-free survival, ELISA = enzyme-linked immunosorbent assay, IHC = immunohistochemistry, LT = liver transplantation, NR = not reported, OPN = osteopontin, OS = overall survive, RT-PCR = reverse transcription-polymerase chain reaction, S = surgical resection, TACE = Transcatheter Arterial Chemotherapy And Embolization.
treatment, our results indicated that the overall HR estimate of surgical resection group for OS was 1.90 (95% CI 1.54–2.33; \( P = .000 \)) (Table 3).

3.4. OPN expression and DFS in HCC

Five studies comprising a total 1054 patients reported results on OPN expression and DFS in HCC. There was no significant heterogeneity (\( P = .304 \), \( I^2 = 17.4\% \)) among them, so a fixed-effect model was used. Pooled data from these studies suggested that increased OPN expression was significantly correlated with poor DFS (HR 1.67; 95% CI 1.40–1.98; \( P = .000 \)), indicating that high OPN expression was an indicator of disease recurrence in HCC patients (Table 3 and Fig. 3). Meanwhile, subgroup analysis by method and treatment indicated a significant association in IHC (HR 1.61; 95% CI 1.33–1.96; \( P = .000 \)), surgical resection (HR 1.61; 95% CI 1.34–1.94; \( P = .000 \)) with DFS, without significant heterogeneity in the data (Table 3).

3.5. Publication bias

Publication bias was assessed by using Begg funnel plot and Egger test (Fig. 4). The results suggested evidence for publication bias in OS studies (Egger, \( P = .012 \)). There was some evidence for publication bias. Meanwhile, we drew a funnel plot and conducted a trim and fill analysis (Fig. 4A). There was some evidence of asymmetry (5 studies trimmed) but the overall effect was strongly influenced by 5 studies, and the overall HR estimate showed that there was no effect of replacing missing studies (adjusted HR HR 1.554; 95% CI 1.227–1.892). There was no significantly different (\( P = .090 \)). While it did not reveal significant publication bias in DFS studies (Egger, \( P = .630 \)).

4. Discussion

The patients with HCC usually have poor prognosis due to late diagnosis and high rate of recurrence. Therefore, it is of great significance to identify the clinical useful markers for predicting prognosis of HCC. In recent years, some studies have shown the potential clinical value of OPN to serve as a biomarker for prognosis and a potential therapeutic target in patients with HCC.\(^{[43,44]}\) And the OPN overexpression could predict late-stage, high-grade, and early-recurrence of HCC.\(^{[24]}\) So, a meta-analysis is needed to systematically evaluate the prognostic value of OPN in hepatocellular carcinoma.

### Table 3

| Heterogeneity | \( \chi^2 \) | \( I^2 \) (%) | \( P \) value |
|---------------|--------------|---------------|-------------|
| OS            |              |               |             |
| Method        |              |               |             |
| RT-PCR        | 3            |               |             |
| ELISA         | 9            |               |             |
| IHC           | 12           |               |             |
| Treatment     | 12           |               |             |
| S             | 16           |               |             |
| LT            | 12           |               |             |
| TACE          | 12           |               |             |
| DFS           | 12           |               |             |
| Method        |              |               |             |
| IHC           | 4            |               |             |
| ELISA         | 12           |               |             |
| Treatment     | 20           |               |             |
| S             | 12           |               |             |
| LT            | 12           |               |             |

### Table 2

| Clinicopathological feature | No. of studies | No. of patient | Model | OR (95% CI) | \( P \) value |
|-----------------------------|----------------|----------------|-------|-------------|-------------|
| Tumor stage (I-II vs. III-IV)| 2              | 545            | Fixed | 1.20 (0.867–1.446) | .386 | .108 | .783 |
| Tumor grade (I-II vs. III-IV)| 6              | 1498           | Random| 2.00 (1.036–3.867) | .039 | .281 | 85.8 | .000 |
| Gender (male vs. female)     | 6              | 1530           | Fixed | 0.928 (0.700–1.230) | .604 | 7.67 | 34.8 | .176 |
| HbsAg (Negative vs. Positive)| 4              | 1351           | Random| 1.106 (0.434–2.820) | .833 | 23.93 | 87.5 | .000 |
| Child grade (A vs. B)        | 3              | 698            | Random| 2.793 (0.869–8.978) | .085 | 4.65 | 57.0 | .098 |
| AFP (<400 vs. >400)          | 3              | 617            | Random| 1.766 (0.987–3.160) | .055 | 5.22 | 61.7 | .074 |
| Liver Cirrhosis (Yes vs. No)| 3              | 999            | Fixed | 0.941 (0.653–1.355) | .742 | 3.00 | 33.3 | .223 |
| Vascular invasion (Yes vs. No)| 5            | 1258           | Random| 2.56 (0.02–7.12) | .073 | 4.18 | 90.4 | .000 |
| Tumor grade (I vs. II–IV)    | 6              | 1498           | Random| 1.196 (0.611–2.336) | .601 | 33.14 | 84.9 | .000 |
| Tumor stage (I–II vs. III–IV)| 2              | 545            | Fixed | 5.680 (3.443–7.758) | .000 | 1.02 | 1.4 | .313 |

\( CI = \) confidence intervals, HCC = hepatocellular carcinoma, OPN = osteopontin, OR = odds ratios.
The first meta-analysis investigating the relationship between OPN and hepatocellular carcinoma prognosis was reported by Zhang et al. Their results included 7 studies suggesting that high OPN expression significantly predicted poor OS and DFS for HCC. Later, Cheng et al. performed a meta-analysis on merely 4 studies and the evidence indicates that plasma OPN can act as an independent prognostic indicator for HCC patients. In recent years, a number of studies have been carried out to analyze the protein expression profiles and prognostic significance of OPN in HCC, but the prognosis utilities of OPN are still controversial. Therefore, we performed a meta-analysis added 5 eligible studies than Zhang et al. in order to provide a quantitative reassessment. And we first performed the subgroup analysis to assess whether the pooled estimate of OS and DFS was different according to the different therapy methods and treatments. So, this meta-analysis may provide reliable and powerful statistics and draw a more conclusive result.

A total of 12 studies with 2117 HCC patients were subjected to quantitative analysis. First of all, we observed that several clinical features were significantly associated with OPN expression. The results of pooled data suggested that high OPN expression significantly correlated with tumor size and TNM stage. In addition, we also analyzed the association of OPN expression with the Child-Pugh stage, AFP, and vascular invasion. An evident trend toward higher OPN expression with the higher Child-Pugh stage and AFP was identified. Taken together, the pooled data of this meta-analysis supported the suggestion that high OPN expression enhanced invasion and metastasis potential of HCC. Meanwhile, the association of OPN with survival of HCC patients was evaluated. The pooled data showed that high OPN expression predicted shorter OS and DFS. These results suggested that OPN is a novel prognostic marker and an indicator of invasiveness in HCC patients. Finally, the subgroup analysis by surgical resection showed that OPN overexpression significantly predicted poorer OS and DFS ($P = .000$, both). Therefore, the pooled results in our study demonstrate that OPN might promote HCC invasion and metastasis, and can serve as a useful biomarker for HCC prognosis.

Some limitations of this meta-analysis should be discussed. First of all, in our meta-analysis, we found significantly heterogeneity among studies for OS ($P = .081$, $I^2 = 38.9\%$), so we used a random-effects model. We then performed a subgroup analysis on methods by RT-PCR, ELISA, IHC, which may influence the heterogeneity. Furthermore, the cutoff value for levels of OPN expression varied in different studies. Different cutoff of OPN expression may impact on the accurate estimation of outcome for HCC, even may cause diametrically opposite results. These reasons may cause the heterogeneity of results. However, the statistical results by subgroup analysis and Sensitivity analysis seemed to be robust and convincing. Therefore, researchers should carry out large multicenter study to develop a definitive cut-off value and establish a method to

![Figure 2](image.png)

**Figure 2.** (A) Forest plot for the relationships between OPN expression and OS. (B) Sensitivity analysis for meta-analysis of OPN. OPN = osteopontin, OS = overall survival.
Figure 2. Continued

Figure 3. Forest plot of hazard ratio for the association of OPN overexpression and DFS. DFS = disease-free survival, OPN = osteopontin.
classify OPN expression. Second, potential risk bias and language were a concern. Because studies with positive results were more likely to be published than negative ones. And we searched literatures written in English. However, the lack of these analyses may affect the reliability of results to some extent, and then reflected our publication bias evaluation. Moreover, the total sample size and the total number of included reports were relatively small. These also might partly influence the validity of our analysis. Third, when we evaluated the correlation between OPN expression and vascular invasion, tumor grade, tumor size, the heterogeneity was significant. However, we could not analysis the source of heterogeneity owing to the limited of studies.

Figure 4. Funnel plots of publication bias in this meta-analysis. (A) OS by trim and fill analysis; (B) DFS by Begg funnel plot. DFS = disease-free survival, OS = overall survival.
Finally, geographical bias was a concern; all patients of the included studies were from Asia, which the dominant risk factor of hepatocellular carcinoma is hepatitis B virus infections, whereas hepatitis C virus-related or alcohol-related hepatocellular carcinoma is the predominant tumor type in Western countries. The OPN expression and its function is still unclear in Western hepatocellular carcinoma patients, because there is no data available till now.

In summary, current available evidence demonstrated the prognostic value of OPN in HCC patients. Our results indicated that OPN can serve as a novel prognostic marker in HCC patients. Due to the limitations of this study, larger and more well-designed studies are still required to clarify the prognostic value of OPN expression in HCC patients.

**Author contributions**

**Conceptualization:** Diwen Sun.

**Data curation:** Tingting Sun.

**Formal analysis:** Peng Li, Qingao Bu.

**Methodology:** Peng Li.

**Project administration:** Peng Li.

**Software:** Guoqiang Li.

**Writing – original draft:** Tingting Sun.

**Writing – review & editing:** Peng Li.

**References**

[1] Venook AP, Papanstereou C, Furuse J, et al. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010;15:5–13.

[2] Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008. GLOBOCAN 2008. Int J Cancer 2010;127:2893–917.

[3] Tang ZY, Ye SL, Liu YK, et al. A decade’s studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol 2004;130:187–96.

[4] Bandopadhyay M, Balbule A, Batti R, et al. Osteopontin as a therapeutic target for cancer. Expert Opin Ther Targets 2014;18:883–95.

[5] Ashkar S, Weber GF, Panoutsakopoulou V, et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 2002;287:864–9.

[6] Shih T. Osteopontin as a two-sided mediator in acute neuroinflammation in rat models. Acta Histochrom 2012;114:749–54.

[7] Hahne JC, Meyer SR, Kranker E, et al. Studies on the role of osteopontin-1 in endometrial cancer cell lines. Stain. Hist. Pathol. Oncol 2013;189:1040–8.

[8] Ramachandran S, Kwon KY, Shin SJ, et al. Regulatory role of osteopontin in malignant transformation of endometrial cancer. Mol Biol Rep 2013;40:3623–9.

[9] Sun J, Xu HM, Zhou HJ, et al. The prognostic significance of preoperative plasma levels of osteopontin in patients with TNM stage-I of hepatocellular carcinoma. J Cancer Res Clin Oncol 2010;136:1–7.

[10] Zhang H, Ye QH, Ren N, et al. The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol 2006;132:709–17.

[11] Ye QH, Qin LX, Forgues M, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med 2003;9:416–23.

[12] Sun BS, Dong QZ, Ye QH, et al. Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma. Hepatology 2008;48:1834–42.

[13] Xue YH, Zhang XF, Dong QZ, et al. Thrombin is a therapeutic target for metastatic osteopontin-positive hepatocellular carcinoma. Hepatology 2010;52:22–22.

[14] Yu TT, Han ZG, Shan L, et al. Expression of osteopontin in non-small cell lung cancer and correlative relation with microvascular density. Asian Pac J Cancer Prev 2014;15:29–32.

[15] Li NY, Weber CE, Mi Z, et al. Osteopontin up-regulates critical epithelial-mesenchymal transition transcription factors to induce an aggressive breast cancer phenotype. J Am Coll Surg 2013;217:17–26.

[16] Bramwell VH, Tuck AB, Chapman JA, et al. Assessment of osteopontin in early breast cancer: correlative study in a randomised clinical trial. Breast Cancer Res 2014;16:R8.
cooperatively contribute to progression and poor prognosis of hepatocellular carcinoma. Int J Oncol 2005;26:1053–61.

[42] Yuan RH, Jeng YM, Chen HL, et al. Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. J Pathol 2006;209:549–58.

[43] Coppola D, Szabo M, Boulware D, et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 2004;10:184–90.

[44] Rittling SR, Chambers AF. Role of osteopontin in tumour progression. Br J Cancer 2004;90:1877–81.

[45] Zhang CH, Xu GL, Jia WD, et al. Prognostic significance of osteopontin in hepatocellular carcinoma: a meta-analysis. Int J Cancer 2012;130:2683–92.

[46] Cheng J, Wang W, Sun C, et al. Meta-analysis of the prognostic and diagnostic significance of serum/plasma osteopontin in hepatocellular carcinoma. J Clin Gastroenterol 2014;48:806–14.